Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tekmira Announces New Appointment to Board of Directors

Published: Saturday, February 15, 2014
Last Updated: Friday, February 14, 2014
Bookmark and Share
Appointment of Ms. Peggy Phillips to Company’s Board of Directors.

Tekmira Pharmaceuticals Corporation has announced the appointment of Ms. Peggy Phillips to its Board of Directors.

"Peggy's appointment and expertise is consistent with our focus on product development. We're confident that her extensive biotechnology experience, senior executive background, and considerable drug development expertise will translate to valuable contributions to our Board and company," said Dr. Mark J. Murray, Tekmira's President and CEO.

The appointment of Ms. Phillips fills the vacancy created in January 2014 when Dr. Michael Abrams resigned from the Board of Directors in order to assume his current role as Tekmira's Chief Discovery Officer. The total number of directors remains at six.

Ms. Phillips was on the Board of Immunex and served as the Chief Operating Officer from 1999 until the company was acquired by Amgen in 2002. During her sixteen-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales, and marketing.

As General Manager for Enbrel, she was responsible for clinical development, process development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for ten years.

Ms. Phillips currently sits on the Board of Directors of Dynavax Technologies (Nasdaq:DVAX), a clinical stage biopharmaceutical company. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tekmira Announces Launch of Arbutus Biopharma
Four HBV product candidates advancing in human clinical trials in 1H16.
Friday, July 24, 2015
Tekmira Provides Periodic Update on TKM-Ebola Program
Commences manufacture of new RNAi therapeutic for Ebola - Guinea variant.
Friday, October 31, 2014
Tekmira Provides Update on RNAi Therapeutic for Ebola
Company commences manufacture of new RNAi therapeutic for Ebola - Guinea variant.
Tuesday, October 21, 2014
Tekmira Joins Ebola International Consortium
Tekmira joins international consortium to conduct clinical trials of Ebola virus therapeutics in West Africa.
Wednesday, September 24, 2014
Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
All other clinical development programs on track.
Thursday, July 24, 2014
Tekmira Initiating Phase I/II Clinical Trial in Patients with HCC
Designed to determine the safety, tolerability and clinical benefit of TKM-PLK1.
Friday, May 30, 2014
Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs
Confirms safety profile of third generation LNP.
Friday, May 23, 2014
Tekmira Secures $3 Million Financing from Silicon Valley Bank (SVB)
The Company plans to use funds from any draw down of the loan to support continued development of its product pipeline and for general corporate purposes.
Thursday, December 22, 2011
Tekmira Pharmaceuticals TKM-Ebola Clinical Trial Approved
Investigational New Drug (IND) application for TKM-Ebola has been approved by the United States FDA, allowing Tekmira to initiate a Phase 1 clinical trial.
Tuesday, November 29, 2011
Tekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb
BMS will use siRNA molecules formulated by Tekmira in stable nucleic acid-lipid particles to silence target genes of interest.
Friday, May 14, 2010
Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial
ApoB SNALP is designed to reduce the production of apolipoprotein B.
Monday, January 11, 2010
Tekmira Pharmaceuticals Announces RNAi Research Collaboration with Bristol-Myers Squibb
Bristol-Myers Squibb to use Tekmira's SNALP technology to deliver siRNAs to specific organs and tissues outside of the liver.
Thursday, August 14, 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination
The combined company, which will retain the name Tekmira, will be a global leader in the field of RNA interference therapeutics.
Monday, June 09, 2008
Tekmira Pharmaceuticals Presents Data on Improved Drug Delivery Technology at International RNAi Conference
Tekmira claims that its improved drug delivery technology has the potential to increase potency to RNAi drugs that are administered intravenously.
Monday, March 31, 2008
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!